History of enteric coated sulfasalazine in rheumatoid arthritis.
Sulfasalazine was synthesized almost 50 years ago specifically to treat rheumatoid arthritis. At that time bacterial infection was believed to be an important factor in pathogenesis. The linkage of sulfapyridine and salicylate with an azobond was viewed as a method of combining antibacterial and antiinflammatory actions while minimizing gastric irritation. Early therapeutic results were encouraging, but the drug was discarded as an antirheumatic agent for 30 years, until its serendipitous rediscovery. Subsequent controlled trials have confirmed its efficacy, which may be related to sulfasalazine itself or to the sulfapyridine moiety.
D000277:Adjuvants, Pharmaceutic / Q000266:history; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D049673:History, 20th Century; D006801:Humans; D012460:Sulfasalazine / Q000008:administration & dosage / Q000266:history; D013608:Tablets, Enteric-Coated
D000277:Adjuvants, Pharmaceutic; D013608:Tablets, Enteric-Coated; D012460:Sulfasalazine